Preclinical and clinical evidence for antifibrotic activity of Galecto’s lead compound, GB0139 (formerly TD139), contained in an abstract for the Experimental Biology 2020 conference
Galecto Inc., of Copenhagen, Denmark, said new data describing the preclinical and clinical evidence for antifibrotic activity of its lead compound, GB0139 (formerly TD139), are contained in an abstract for the Experimental Biology 2020 conference. Galecto is developing GB0139 to treat most forms of lung fibrosis with an initial focus on idiopathic pulmonary fibrosis (IPF).
